Minoxidil Cyclodextrin Inclusion Complex-Loaded Microemulsions and Transfersomes for Androgen Alopecia Treatment: A Comparative Study

In this study, the researchers reported that minoxidil-loaded transfersomes using a cyclodextrin strategy significantly increased drug stability, skin permeation, and hair regrowth in a mouse model of androgenetic alopecia compared to traditional formulations and commercial tinctures.

This study found that combining minoxidil with ginsenosides Rg3 in a novel delivery system improved hair growth by reducing inflammation and oxidative stress in androgen alopecia treatments.

This study found that combining the natural product cedrol with minoxidil can improve the treatment of androgenetic alopecia by reducing the minoxidil dose needed, while a new nanocarrier system enhances drug delivery and effectiveness at hair follicles.

In a mouse model of androgenetic alopecia, this study developed a treatment combining a copper-curcumin nanoparticle oleogel with traditional Gua Sha therapy, which augmented hair regeneration more effectively than minoxidil by improving the follicular microenvironment and regulation of inflammatory responses.

This review highlights potential therapeutic mechanisms of natural products for androgenetic alopecia, suggesting they may modulate signaling pathways and have anti-inflammatory and antioxidant effects.

This study developed a novel liposome-based delivery system for Minoxidil and nitric oxide, which showed promising results in promoting hair regrowth in an androgenetic alopecia model by enhancing transdermal absorption, prolonging skin retention, and reducing inflammation.

This study found that ethosome-loaded minoxidil and tocopherol acetate improved hair regeneration and regulated the microenvironment around hair follicles better than commercial minoxidil in androgenic alopecia model mice, showing promise as a treatment strategy.

This study found that finasteride niosomes may enhance hair follicle drug accumulation and promote hair regeneration in androgenetic alopecia mice more effectively than current finasteride formulations.

This review examines the efficacy of various novel treatments for androgenetic alopecia, including oral minoxidil and platelet-rich plasma, suggesting potential benefits but emphasizing the need for further high-quality clinical trials to thoroughly evaluate their effectiveness.

This study reported that optimized transfersomes and their gel form significantly improved transdermal delivery and hair growth promotion of minoxidil in C57BL/6 mice compared to commercial formulations.

This study concluded that both oral and topical spironolactone effectively treat androgenetic alopecia, with topical administration being safer and suitable for any gender, especially when combined with minoxidil.

This review explores medicinal plants as potential treatments for hair loss, suggesting their promise due to anti-inflammatory and antioxidant properties, but reports no new clinical results.

This study suggests that using cholesterol-free liposomes, specifically PPD-Lip, as a delivery system with dutasteride may enhance the treatment of androgenetic alopecia by promoting hair regrowth in mice models.

This study reported that 5% minoxidil nanoparticles enhanced hair growth more effectively in mice than a commercial minoxidil solution, with significantly higher drug accumulation in the upper hair follicles.

Natural products like saw palmetto, caffeine, melatonin, marine extracts, rosemary oil, procyanidin, pumpkin seed oil, and cannabidiol oil could potentially treat male hair loss.

This study found that a ceria nanozyme-integrated microneedles patch accelerated hair regeneration in an androgenetic alopecia mouse model more effectively than minoxidil, with reduced application frequency and minimal skin damage.

This study suggests that policosanol may prevent androgenetic alopecia in mice by regulating hormone levels and suppressing premature hair follicle entry into the regression phase.

In this study, exosome-mimetic nanovesicles derived from neural progenitor cells promoted hair follicle regeneration in mice by activating the Wnt/β-catenin signaling pathway.

In this study, a mixture of tocopherol acetate, L-menthol, and stevioside was more effective in promoting hair growth in mice compared to tocopherol acetate or L-menthol alone.

This study used melamine formaldehyde particles to measure a pH gradient along the hair shaft, showing a significant pH decrease from the hair sheath to the external shaft.

This review discusses the use of topical minoxidil for various types of alopecia and reports mixed evidence on its efficacy, with stronger support noted for conditions like eyebrow hypotrichosis and chemotherapy-induced alopecia.

This study suggests that minoxidil may enhance hair growth by stimulating adipose-derived stem cell motility and growth factor secretion, promoting dermal papilla cell proliferation and accelerating anagen induction.

This study found that co-delivery of minoxidil and caffeine in transfersomes with an optimized polysorbate formulation enhanced hair length and weight in vivo.

This research investigated aqueous alginate-based hydrogels for delivering minoxidil and reported that using hydroxypropyl-β-cyclodextrin (HP-β-CD) with molar substitution 0.65 significantly enhanced minoxidil's solubility and skin permeability without damaging the epidermis, suggesting potential as an alternative to commercial minoxidil solutions.

This review discusses the potential benefits of activating NRF2 for treating hair follicle disorders linked to oxidative stress and reports no new clinical results.

This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.

This study found that Ecklonia cava polyphenols increased human dermal papilla cell proliferation and extended hair shaft length in vitro and ex vivo, suggesting potential as a therapeutic candidate for hair loss.

This article discusses the social and psychological impact of hair disorders and the challenges in their treatment, but reports no new clinical results.

This study developed minoxidil sulphate-loaded chitosan nanoparticles that doubled drug delivery to hair follicles in vitro compared to a control solution, suggesting potential for improved alopecia treatment.

This study found that an optimized microemulsion for minoxidil with high solubility, permeation flux, and skin deposition can be achieved with specific low and high levels of certain surfactants and co-solvents.

This study found that minoxidil-loaded niosomes with a Span 60 and cholesterol ratio of 1:2 significantly increased skin retention of minoxidil compared to control gel.

This study observed that androgen treatment increased ROS production and TGF-β1 secretion in rat hair follicle dermal papilla cells, suggesting that the androgen-induced TGF-β1 is mediated by ROS.

This pilot study found that a multimodal minoxidil microemulsion with diclofenac and tea tree oil was more effective and safer than minoxidil alone for treating androgenic alopecia over 32 weeks.

This study demonstrated that tocotrienol supplementation increased hair number in individuals with hair loss compared to a placebo, likely due to its antioxidant effects.

This study found that polymeric nanoparticles retained more minoxidil and facilitated superior drug permeation compared to lipid nanoparticles, although premature drug release affected formulation performance.

This study found that testosterone and 5α-dihydrotestosterone induced apoptosis in dermal papilla cells from nonbalding scalp regions, suggesting a high androgen stimulus can trigger cell death related to androgenetic alopecia.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

Minoxidil boosts hair growth by targeting adenosine and possibly sulfonylurea receptor 2B.